pharmaceutical investing AbbVie Announces Positive CHMP Opinion for MAVIRET® for the Treatment of Acute Hepatitis C Infection
pharmaceutical investing AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
pharmaceutical investing Allergan Aesthetics Receives Positive CHMP Opinion for Boey® for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults
pharmaceutical investing AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases at 2026 Digestive Disease Week®
pharmaceutical investing SKYRIZI® Secures Listing on Ontario and Alberta Formularies in Ulcerative Colitis
pharmaceutical investing AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec
pharmaceutical investing AbbVie Submits Application to FDA for Upadacitinib for Adults and Adolescents with Severe Alopecia Areata
pharmaceutical investing RINVOQ® Demonstrated Superiority Versus HUMIRA® for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF inhibitor
pharmaceutical investing EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie
pharmaceutical investing AbbVie Submits Regulatory Application to FDA for SKYRIZI® Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
pharmaceutical investing AbbVie Provides Update on TrenibotulinumtoxinE Biologics License Application in the U.S.
Quebec Innovative Materials:Advancing Canadian and American Natural Hydrogen for the Next Energy Cycle
